[ABSTRAK
Gejala utama kanker paru adalah sesak yang dapat menyebabkan depresi, cemas,keterbatasan aktivitas mandiri serta menurunkan kualitas hidup. Tujuan daripenelitian ini adalah untuk mengidentifikasi pengaruh stimulasi aliran udara darihand-held fan sebagai intervensi paliatif nonfarmakologis terhadap sesak padapasien kanker paru. Penelitian ini menggunakan randomized controlled crossoveropen trial design dan melibatkan 21 subjek. Kontrol yang digunakan sebagaipembanding adalah teknik pernafasan diafragma. Hasil uji Wilcoxonmenunjukkan bahwa stimulasi aliran udara dari hand-held fan mempengaruhiskala sesak (p= 0,003) dan frekuensi pernapasan (p= 0,008) secara signifikan.Intervensi tersebut dapat dilakukan pada pasien kanker paru sesak nonhipoksemia.

---

ABSTRACT
The main symptom of lung cancer is dyspnea which can lead to depression,anxiety, limited independent activities and decreased quality of life. The purposeof this study was to identify the effect of airflow stimulation from hand-held fan asnon-pharmacological palliative intervention on dyspnea in patients with lungcancer. This study used open randomized controlled crossover trial designinvolved 21 subject. Diaphragmatic breathing technique was used in control arm.Wilcoxon test result showed that airflow stimulation significantly influenceddyspnea scale (p= 0.003) and respiratory rate (p=0.008). This intervention canbe applied on nonhypoxemic dyspneic lung cancer patients, The main symptom of lung cancer is dyspnea which can lead to depression,anxiety, limited independent activities and decreased quality of life. The purposeof this study was to identify the effect of airflow stimulation from hand-held fan asnon-pharmacological palliative intervention on dyspnea in patients with lungcancer. This study used open randomized controlled crossover trial designinvolved 21 subject. Diaphragmatic breathing technique was used in control arm.Wilcoxon test result showed that airflow stimulation significantly influenceddyspnea scale (p= 0.003) and respiratory rate (p=0.008). This intervention canbe applied on nonhypoxemic dyspneic lung cancer patients]